Humanized Anti-CD40 Antibodies for Blocking CD40 Signaling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments lack effective therapeutic agents that can intervene in the CD40-CD40L interaction and block CD40 signaling, which is crucial for suppressing pathogenic autoimmune responses in diseases such as rheumatoid arthritis and systemic lupus erythematosus, and there is a need for interventions in graft-versus-host disease and graft rejection.
Innovation Solution
Development of humanized anti-CD40 antibodies with specific antigen-binding properties and pharmacokinetic profiles, combined with tacrolimus, to block CD40 signaling and treat autoimmune diseases and graft-related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used, then existing therapeutic options are available, but effective intervention in CD40-CD40L interaction and blocking of CD40 signaling is lacking
Solution Approach 1:
The patent introduces anti-CD40 antibodies as intermediary molecules that specifically bind to CD40 receptors, blocking the interaction between CD40 and its ligand CD40L. This intermediary approach allows selective intervention in the CD40 signaling pathway without affecting other immune pathways, thereby improving therapeutic efficacy for autoimmune diseases while maintaining targeted adaptability.
2Object-affected harmful factors
If CD40 signaling is blocked to suppress autoimmune responses, then pathogenic immune responses are reduced, but graft-versus-host disease and graft rejection require additional intervention strategies
Solution Approach 1:
The patent develops anti-CD40 antibodies with universal applicability across multiple disease indications. By targeting the conserved CD40 receptor expressed on various immune cells (B cells, dendritic cells, macrophages), the antibody provides multi-functional therapeutic effects: suppressing autoimmune responses in diseases like rheumatoid arthritis and lupus, while also preventing graft-versus-host disease and graft rejection. This universal mechanism allows one therapeutic agent to address multiple harmful immune pathologies.
Data Source
AI summary
Provided are an anti-CD40 antibody, an antigen-binding fragment and a medical use thereof, as well as a pharmaceutical composition containing the anti-CD40 antibody or antigen-binding fragment thereof, and a method for treating and preventing disease, in particular a method for treating autoimmune disease.